Ergoteles LLC Halozyme Therapeutics, Inc. Transaction History

Ergoteles LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $462,315 - $591,482	-15,268 Reduced 41.34%	21,664 $781,000
Q1 2023 May 10, 2023	BUY	$32.86 - $55.7 $972,853 - $1.65 Million	29,606 Added 404.12%	36,932 $1.41 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $293,479 - $435,457	7,326 New	7,326 $416,000
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $825,785 - $1.06 Million	-25,830 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $821,910 - $1.05 Million	25,830 New	25,830 $1.04 Million
Q2 2021 Aug 12, 2021	SELL	$38.84 - $51.31 $916,624 - $1.21 Million	-23,600 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$39.51 - $51.45 $932,436 - $1.21 Million	23,600 New	23,600 $984,000
Q4 2020 Feb 11, 2021	SELL	$25.81 - $43.62 $214,223 - $362,046	-8,300 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $213,642 - $245,929	8,300 New	8,300 $218,000

542

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.35B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.